Author: Site Editor Publish Time: 2026-10-29 Origin: Site
China's 15th Five-Year Plan for the Pharmaceutical Industry: What the 2030 Targets Change
On 18 September 2026, the Ministry of Industry and Information Technology (MIIT) and nine other departments released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry (MIIT Joint Plan [2026] No. 210). The plan sets the industry's objectives to 2030 and guides the next five years of policy. It lists ten expected indicators, including operating revenue above RMB 3.5 trillion for pharmaceutical enterprises above designated size, first-in-class (FIC) drugs accounting for more than 25% of the global total, annual growth of the innovative drug sector above 20%, and more than 200 innovative medical devices approved for market. Eight areas and 25 key tasks cover innovation, supply chain resilience, artificial intelligence, digital and green transformation, clinical translation and international cooperation.
China's 15th Five-Year Plan for the Pharmaceutical Industry: What the 2030 Targets Change
On 18 September 2026, the Ministry of Industry and Information Technology (MIIT) and nine other departments released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry (MIIT Joint Plan [2026] No. 210). The plan sets the industry's objectives to 2030 and guides the next five years of policy. It lists ten expected indicators, including operating revenue above RMB 3.5 trillion for pharmaceutical enterprises above designated size, first-in-class (FIC) drugs accounting for more than 25% of the global total, annual growth of the innovative drug sector above 20%, and more than 200 innovative medical devices approved for market. Eight areas and 25 key tasks cover innovation, supply chain resilience, artificial intelligence, digital and green transformation, clinical translation and international cooperation.
Ten indicators, one direction
The 2030 targets are quantitative and largely measurable. The headline numbers:
operating revenue of pharmaceutical enterprises above designated size above RMB 3.5 trillion
average annual growth of the innovative drug sector above 20%
average R&D intensity of listed pharmaceutical companies at or above 10% per year
FIC drugs developed in China at 25% or more of the global total
200 or more innovative medical devices approved
5 or more products with global annual sales above USD 1 billion
50 or more pharmaceutical companies with revenue above RMB 10 billion
20 or more industrial parks with output value above RMB 100 billion
Two further indicators are positional rather than numeric: the number of new drug candidates entering first-in-human trials, and the number of innovative drugs approved, should both rank among the world's leading. All ten are expected indicators — indicative planning figures rather than binding caps or quotas. That distinction matters when the numbers are quoted in investor or partner materials.
Eight directions, 25 tasks
The tasks are grouped under eight headings: innovation-driven development, resilient and secure supply, digital-intelligent transformation, precision diagnosis and treatment, efficiency gains, value creation, inclusive health, and open, mutually beneficial cooperation.
Alongside the task list, the plan creates nine dedicated columns covering priority innovation areas and high-value AI applications in drug discovery, including AI-enabled target screening and molecular design, and R&D support for rare disease therapies.
Innovation capability and international reach
The plan puts original innovation first: strengthening discovery capability, completing the clinical translation and engineering scale-up chain, and pushing AI into R&D, manufacturing and quality control. Frontier modalities named in the document include antibody-drug conjugates (ADC), nucleic acid therapeutics and cell and gene therapies (CGT).
On the international side, the plan supports Chinese companies in running international multi-regional clinical trials, expanding overseas operations, and bringing domestic drugs and devices into international markets. It also sets out measures to accelerate the approval of urgently needed imported products and to attract their manufacture onshore — a two-way framing that matters for companies deciding where to place capacity.
The gaps the plan names itself
The document is explicit that the industrial base is uneven. High-end pharmaceutical equipment, analytical and testing instruments, and key raw and auxiliary materials remain weak links that must be closed, with risk-monitoring and response mechanisms to be improved.
It also calls for developing CRO and CDMO models as specialized service formats — a signal that outsourced development and manufacturing are treated as part of the industrial infrastructure rather than an adjunct to it. Higher demands are set for digital and green transformation, quality control, and supply chain coordination across the sector.
Loncom's view
What this means for partners
Read as policy direction rather than a funding announcement, the plan moves the basis of competition from single-point R&D capability to the whole chain: whether a result can be translated, manufactured at scale, released compliantly, and delivered into a target market.
For pharmaceutical companies and for development and manufacturing service organizations, the practical response is to assess capability gaps in process development, quality control, industrialization handover and international business — and to convert the policy direction into specific development and operating plans rather than treating it as background reading.
Loncom will continue to track the plan and its supporting policies, and will keep strengthening the link between R&D and industrialization, quality compliance and international cooperation, in line with the actual project needs of its partners.
FAQ
Who issued the plan and when?
MIIT, together with the National Development and Reform Commission, the National Medical Products Administration and seven other departments, released it on 18 September 2026 as MIIT Joint Plan [2026] No. 210.
Are the ten indicators binding targets?
No. They are expected (indicative) indicators. They signal direction and scale rather than imposing mandatory quotas on individual companies.
Which therapeutic areas are prioritized?
The plan names ADC, nucleic acid therapeutics and cell and gene therapy as frontier tracks, together with rare disease therapies and AI-enabled drug discovery.
What does it mean for international partners?
Two things in particular: continued policy support for outbound clinical development and overseas market entry, and an explicit push to close gaps in equipment, instruments and key materials — both of which affect sourcing and partnering decisions.
Conclusion
The 15th Five-Year Plan is less a list of subsidies than a statement about where the Chinese pharmaceutical industry intends to sit in global value chains by 2030: earlier in discovery, more capable in manufacturing, and more present in international markets. For partners outside China, the useful question is not whether the targets are ambitious, but which parts of the chain they will need to rely on.
Source: Ministry of Industry and Information Technology and nine other departments, 15th Five-Year Plan for the Development of the Pharmaceutical Industry (MIIT Joint Plan [2026] No. 210), released 18 September 2026.
